Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review

Clin Genitourin Cancer. 2015 Dec;13(6):e391-5. doi: 10.1016/j.clgc.2015.07.003. Epub 2015 Jul 26.

Authors

Wenge Wang¹, Jihua Cheng², Carol Mallon², Mohammed Y Al-Marrawi², Sheldon Holder², Monika Joshi², Matthew Kaag², Giampaolo Talamo², Joseph J Drabick²

Affiliations

¹ Hematology-Oncology and Urology Divisions, Penn State Milton S. Hershey Medical Center and Cancer Institute, Hershey, PA. Electronic address: wwang3@hmc.psu.edu.
² Hematology-Oncology and Urology Divisions, Penn State Milton S. Hershey Medical Center and Cancer Institute, Hershey, PA.

PMID: 26303589
DOI: 10.1016/j.clgc.2015.07.003

No abstract available

Keywords: Axitinib; Bevacizumab; Erythropoietin; Hypoxia induced factor; Pazopanib; Phlebotomy; Sorafenib; Tyrosine kinase inhibitors.

Publication types

Case Reports
Review

MeSH terms

Adult
Aged
Antineoplastic Agents / adverse effects*
Carcinoma, Renal Cell / complications
Carcinoma, Renal Cell / drug therapy*
Female
Humans
Kidney Neoplasms / complications
Kidney Neoplasms / drug therapy*
Male
Middle Aged
Neoplasm Metastasis
Phlebotomy
Polycythemia / chemically induced*
Polycythemia / therapy
Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

Antineoplastic Agents
Vascular Endothelial Growth Factor A